ADVFN - Advanced Financial Network.
HOME» NASDAQ » C » CELG Stock Price » CELG Stock News

Celgene Share News

 Celgene (mm) Stock Price
CELG Stock Price
 Celgene (mm) Stock Chart
CELG Stock Chart
 Celgene (mm) Stock News
CELG Stock News
 Celgene (mm) Company Information
CELG Company Information
 Celgene (mm) Stock Trades
CELG Stock Trades

Abraxis Deal Value Depends On CVRs; CVRs Seen Undervalued

By Maxwell Murphy Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Abraxis BioScience Inc. (ABII) shares soared past the merger bid proposed by Celgene Corp. (CELG), but it's not because Wall Street thinks a higher offer will materialize. It's all about the contingent value rights. As part of the deal, Abraxis holders will get one contingent value right for each Abraxis share they own. These rights, which will be tradable, allow the holder to receive a prorated share of future payments that are mostly conditioned on Abraxis' Abraxane chemotherapy treatment meeting certain targets. CVR holders will split $250 million for U.S. approval of Abraxane, by the Food and Drug Administration, for a type of lung cancer, whereby the drug is allowed to be labeled with what's called "progression-free survival" claims. If Abraxane is approved for pancreatic cancer and can add overall survival claims to the label, that's another $300 million. Further, if Abraxane, currently a breast-cancer treatment, is simply approved for pancreatic cancer by the FDA by April 1, 2013, holders will get another $100 million. Additional royalty payments could ensue if Abraxane and certain other Abraxis pipeline products meet as-yet-undisclosed net revenue targets. If all the conditions are met, CVR holders stand to pocket more than $650 million, or over $16 per CVR given the roughly 40.4 million Abraxis shares outstanding. Apart from the CVRs, the upfront payment Abraxis holders will receive consists of $58 in cash and about 0.26 Celgene shares. At Celgene's Tuesday closing price, that works out to about $71.93 per Abraxis share, but with Celgene off 4.1% in recent trading the value has shrunk to about $71.33 apiece. Abraxis shares recently traded 21.4% higher at $74.40 each, which suggests investors are currently valuing the CVRs at roughly $3 apiece. At least one investor believes that is a low valuation, which would mean Abraxis stock could still present a buying opportunity. Dr. Jeffrey Jay, managing director of hedge-fund company Great Point Partners LLC, sees the CVRs as worth $5 to $7 each, "depending on the assumptions you want to make." He said the CVRs are essentially "complicated call options on contingent, probability weighted events (favorable clinical outcome and trials and a favorable review by the FDA)." Great Point, which held just over 66,000 Abraxis shares at the end of March, believes the current market valuation of the CVRs "is below fair value under any but the most pessimistic set of assumptions about future clinical and regulatory events." However, given the FDA-approval variables and the uncertain, indefinite time horizon surrounding three of the four milestones, assessing the present value of the CVRs is not without difficulties. One savvy Abraxis investor who requested anonymity said his firm was still evaluating the potential value of the CVRs. Normally, a valuation uncertainty like this might present a field day for arbitrageurs, who seek to make money on pricing inefficiencies. But one New York arbitrageur said a lack of Abraxis liquidity--Executive Chairman Patrick Soon-Shiong owns some 82% of its stock--and the scientific expertise needed to evaluate the CVRs has his firm on the sidelines. -By Maxwell Murphy, Dow Jones Newswires; 212-416-2171; maxwell.murphy@dowjones.com

Stock News for Celgene (CELG)
DateTimeHeadline
04/24/201508:53:10AstraZeneca Reports Fall in First-Quarter Profit -- 2nd Update
04/24/201505:11:32AstraZeneca Reports Fall in First-Quarter Profit -- Update
04/24/201504:03:10Correction to Story on AstraZeneca First-Quarter Earnings
04/24/201503:30:04AstraZeneca Reports Fall in First-Quarter Profit
04/24/201503:11:35AstraZeneca Reports Fall in First-Quarter Profit
04/24/201501:04:00Celgene Corp. Enters into Strategic Immuno-Oncology Collaboration...
04/23/201517:43:00POMALYST® (pomalidomide) Label Update Including Progression-Free...
04/23/201508:30:00Celgene Corporation to Webcast at Upcoming Investor Conferences...
04/21/201513:06:023 Questions to Ask Before You Buy a Biotech Stock
04/20/201516:11:51Current Report Filing (8-k)
04/19/201514:02:02How to Invest Money in Biotech
04/17/201501:00:00Publication des données de lâétude de phase II portant sur lâa...
04/16/201501:00:00Phase-II-Daten zu Apremilast Bei Morbus Behçet im New England J...
04/15/201517:04:07Initial Statement of Beneficial Ownership (3)
04/15/201517:03:00Phase II Data for Apremilast in Behçetâs Disease Published in...
04/15/201508:42:30Current Report Filing (8-k)
04/15/201507:30:00Celgene Corporation Elects Mr. Michael W. Bonney to Its Board...
04/13/201503:30:32Australia Shares End Down, Weighed by China Trade Data
04/12/201521:00:49Celgene Buys Mesoblast Stake
04/12/201519:46:28Celgene Buys Mesoblast Stake

Celgene and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad